Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ICT) is a biopharmaceutical company headquartered in New York, NY, focused on the development and commercialization of therapeutics for neuropsychiatric and neurological disorders. The company was founded in 2003 by Dr. Sharon M. W. Rosenberg and Dr. Robert L. B. Nahas, with a focus on intracellular signaling pathways.

Overview

Intra-Cellular Therapies, Inc. (ICT) is a biopharmaceutical company headquartered in New York, NY, focused on the development and commercialization of therapeutics for neuropsychiatric and neurological disorders. The company was founded in 2003 by Dr. Sharon M. W. Rosenberg and Dr. Robert L. B. Nahas, with a focus on intracellular signaling pathways.

Overview

Intra-Cellular Therapies is dedicated to developing novel treatments for CNS disorders by targeting intracellular signaling pathways within neurons. The company's scientific platform integrates expertise in receptor pharmacology, intracellular signaling, and medicinal chemistry to develop compounds with improved efficacy and safety profiles["@lumateperone"].

Funding

• IPO: 2014 (NASDAQ: ITCI)
• Market Cap: ~$10B (2026)

Corporate Highlights

• Founded: 2003
• Headquarters: New York, New York
• Employees: Approximately 600
• NASDAQ: ITCI
• Market Cap: Approximately $4 billion USD (2025)

History and Development

Company Formation (2003)

Clinical Development (2003-2019)

• 2003-2010: Built pipeline of novel CNS compounds
• 2010-2015: Advanced lumateperone through Phase 1 and 2 trials
• 2015-2019: Completed Phase 3 trials for schizophrenia
• 2019: FDA approval of CAPLYTA for schizophrenia

Commercial Stage (2020-Present)

• 2021: FDA approval of CAPLYTA for bipolar depression
• 2022: FDA approval of ZTALMY for CDKL5 deficiency disorder
• 2024: CAPLYTA sales reached approximately $450 million

Approved Products

CAPLYTA (Lumateperone)

CAPLYTA is the company's flagship product, representing a novel approach to treating schizophrenia and bipolar depression[@caplyta]:

• FDA Approval: December 2019 (Schizophrenia)
• Additional Approval: December 2021 (Bipolar depression)
• Mechanism: Multimodal dopamine D2 and serotonin 5-HT2A receptor partial agonist
• Significance: First and only approved dopamine D2 partial agonist with 5-HT2A antagonism for schizophrenia

• Reduced extrapyramidal symptoms compared to traditional antipsychotics
• Minimal metabolic side effects (weight, lipids, glucose)
• Improved cognitive function potential
• Once-daily oral dosing
• Broad symptom coverage (positive, negative, cognitive)

• Phase 3 trials showed statistically significant improvement in PANSS scores
• Lower rates of akathisia, prolactin elevation, and weight gain vs. placebo
• Improvement in depression symptoms in bipolar depression trials

ZTALMY (Ganaxolone)

ZTALMY represents a breakthrough in rare disease treatment[@ztalmy]:

• FDA Approval: March 2022
• Indication: Seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)
• Mechanism: GABA-A receptor modulator (synthetic analog of allopregnanolone)
• Significance: First and only FDA-approved treatment for CDKL5 deficiency disorder
• Formulation: Oral suspension (weight-based dosing)

Pipeline Programs

Clinical Development

| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| Lumateperone | Bipolar depression | D2/5-HT2A partial agonist | Phase 3[@lumateperone2021] |
| Lumateperone | Alzheimer's disease psychosis | D2/5-HT2A partial agonist | Phase 2 |
| Lumateperone | Major depressive disorder | D2/5-HT2A partial agonist | Phase 2 |
| ITI-333 | Opioid use disorder | Mu opioid receptor antagonist | Phase 1 |
| ITI-1284 | Neurological disorders | PDE4 modulator | Preclinical |

Science and Technology

Multimodal Receptor Activity

• Dopamine D2: Partial agonist (reduces both excess dopamine and dopamine deficiency)
• Serotonin 5-HT2A: Antagonist (reduces hallucinations and psychosis)
• D1: Partial agonist (may improve cognitive function)
• 5-HT1A: Partial agonist (potential antidepressant effects)

GABA Modulation

Financial Highlights

• Market Cap: Approximately $4 billion USD (2025)
• Revenue (2024): Approximately $450 million USD (CAPLYTA sales)
• R&D Investment: Approximately $200 million USD annually
• Key Investors: BlackRock, Vanguard, Franklin Templeton

Neurological Relevance

Intra-Cellular's pipeline addresses significant unmet needs in neuropsychiatry[@alzheimers]:

Schizophrenia

• Treatment of positive, negative, and cognitive symptoms
• Reduced risk of metabolic syndrome
• Potential for improved long-term outcomes

Alzheimer's Disease Psychosis

• Current treatments (risperidone, olanzapine) have limited efficacy and significant side effects
• Lumateperone's favorable safety profile may address this population
• Phase 2 trials showed promising results[@lumateperonea]

CDKL5 Deficiency Disorder

• Affects approximately 1 in 40,000-60,000 live births
• Causes intractable seizures and developmental delay
• ZTALMY provides first disease-specific treatment option

Major Depressive Disorder

• Lumateperone's novel mechanism may offer benefits
• Phase 2 trials showed antidepressant effects
• [Schizophrenia](/diseases/schizophrenia)
• [Bipolar Disorder](/genes/ar)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Psychosis](/therapeutics/nelotanserin-parkinsons-psychosis)
• [CDKL5 Deficiency Disorder](/genes/cdkl5)
• Major Depressive Disorder
• CAPLYTA
• ZTALMY
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [GABA Signaling](/mechanisms/gaba-signaling)
• [Serotonin Signaling](/mechanisms/serotonin-signaling)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References